Hospital
ST Jude Hospital INC
ST Jude Hospital INC was paid $21.22M by Medicaid between Jan 2018 and Dec 2024, across 368 billing codes. Its largest line is 0450, Emergency room services — 6.1% of everything it billed.
33Billing provider infoST JUDE HOSPITAL INC
FULLERTON, CA 92835
FULLERTON, CA 92835
33aNPI1194926279assigned 05/29/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$21.22M
24GClaims1,264,263
24DCodes billed368
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#118 of 410
Median peer was paid$6.90M
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 173,337 | $2.13M | |
| 2019 | 158,098 | $2.58M | |
| 2020 | 174,610 | $2.35M | |
| 2021 | 201,252 | $2.88M | |
| 2022 | 212,242 | $3.23M | |
| 2023 | 212,563 | $4.19M | |
| 2024incomplete | 132,161 | $3.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 6.1% | 79,974 | 70,540 | $1.30M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.0% | 10,733 | 10,028 | $1.05M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.9% | 32,192 | 11,041 | $834K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.7% | 9,639 | 9,327 | $788K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 3,987 | 3,763 | $740K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 12,427 | 11,527 | $723K |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 2.9% | 13,484 | 9,496 | $614K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.5% | 32,919 | 29,083 | $529K |
| Z7502 | 2.5% | 13,897 | 13,756 | $525K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 12,761 | 10,867 | $513K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.3% | 16,119 | 11,401 | $497K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.3% | 4,180 | 3,860 | $478K |
356 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.2% | 10,950 | $469K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 8,454 | $448K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 70,720 | $404K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.9% | 6,085 | $398K |
| 80053 | Comprehensive metabolic panel | 1.8% | 48,039 | $387K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.8% | 19,962 | $384K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 6,609 | $307K |
| 83880 | 1.3% | 13,231 | $285K | |
| J3490 | Unclassified drugs | 1.2% | 46,356 | $256K |
| 97750 | 1.2% | 4,869 | $254K | |
| 84145 | 1.2% | 15,385 | $249K | |
| 99285 | Emergency room visit (most serious) | 1.1% | 6,511 | $238K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 25,501 | $229K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.1% | 8,126 | $225K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.0% | 5,506 | $215K |
| 99199 | Unlisted special service, procedure or report | <1% | 3,934 | $207K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,056 | $198K |
| 76830 | Ultrasound, transvaginal | <1% | 3,489 | $194K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,176 | $192K |
| 84484 | <1% | 27,293 | $190K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,690 | $169K |
| 93971 | <1% | 1,804 | $167K | |
| 93976 | <1% | 2,626 | $162K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 115 | $159K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 981 | $159K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,536 | $153K |
| 83605 | <1% | 19,676 | $147K | |
| 87040 | <1% | 19,261 | $146K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,140 | $146K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,656 | $144K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,154 | $141K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,507 | $127K |
| G0378 | Hospital observation service, per hour | <1% | 673 | $123K |
| 96367 | <1% | 3,683 | $120K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 23,125 | $119K |
| 70496 | <1% | 689 | $107K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,456 | $102K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 694 | $95K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,647 | $95K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,852 | $93K |
| 99283 | Emergency room visit (moderate) | <1% | 5,511 | $91K |
| 93307 | <1% | 980 | $90K | |
| 76801 | <1% | 1,641 | $88K | |
| 83690 | <1% | 17,865 | $87K | |
| 80061 | Lipid panel | <1% | 6,457 | $81K |
| 93970 | <1% | 537 | $81K | |
| 72100 | <1% | 3,527 | $77K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,223 | $75K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,603 | $72K |
| 97010 | <1% | 2,466 | $70K | |
| 97139 | <1% | 3,175 | $69K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,979 | $68K |
| 70498 | <1% | 694 | $67K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 374 | $66K |
| 81001 | <1% | 30,448 | $65K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 323 | $65K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,953 | $63K |
| 73630 | <1% | 3,470 | $61K | |
| 76641 | <1% | 935 | $60K | |
| 99284 | Emergency room visit (serious) | <1% | 2,692 | $59K |
| 90715 | <1% | 1,978 | $57K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,118 | $56K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,418 | $55K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 390 | $52K |
| 85730 | <1% | 14,079 | $52K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 133 | $51K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,367 | $51K |
| 73030 | <1% | 2,965 | $50K | |
| 76536 | <1% | 1,026 | $49K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,248 | $47K |
| 85610 | <1% | 18,448 | $46K | |
| 73610 | <1% | 2,603 | $45K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 5,163 | $45K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,220 | $45K |
| 77066 | Tomosynthesis, mammo | <1% | 339 | $44K |
| 72040 | <1% | 1,892 | $43K | |
| 71250 | <1% | 551 | $42K | |
| 73562 | <1% | 2,620 | $41K | |
| 96415 | <1% | 1,361 | $41K | |
| 70486 | <1% | 549 | $40K | |
| 73502 | <1% | 1,780 | $39K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,610 | $39K |
| 73130 | <1% | 2,142 | $37K | |
| 97165 | <1% | 855 | $36K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,620 | $35K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 699 | $35K |
| 73564 | <1% | 1,811 | $34K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 977 | $34K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,659 | $33K |
| 76775 | <1% | 1,217 | $32K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 350 | $32K |
| 59025 | Fetal non-stress test | <1% | 1,341 | $31K |
| 96417 | <1% | 743 | $27K | |
| 76642 | <1% | 448 | $27K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,578 | $26K |
| 0250 | <1% | 8,541 | $26K | |
| 83735 | <1% | 5,736 | $25K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 961 | $25K |
| 73110 | <1% | 1,420 | $24K | |
| 0160 | <1% | 2,305 | $23K | |
| 0240U | <1% | 572 | $22K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,426 | $22K |
| 84703 | <1% | 12,264 | $22K | |
| 97162 | <1% | 1,413 | $22K | |
| 85379 | <1% | 2,749 | $22K | |
| 87186 | <1% | 3,594 | $22K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 198 | $21K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,786 | $21K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 446 | $21K |
| C1769 | Guide wire | <1% | 760 | $20K |
| 84702 | <1% | 2,990 | $20K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 699 | $19K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,371 | $19K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 108 | $19K |
| 82948 | <1% | 5,859 | $19K | |
| 87077 | <1% | 3,454 | $19K | |
| 74018 | <1% | 1,675 | $18K | |
| 96376 | <1% | 5,703 | $18K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,131 | $18K |
| Z7610 | <1% | 4,072 | $18K | |
| 97116 | <1% | 1,614 | $17K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,748 | $17K |
| 85027 | <1% | 4,588 | $17K | |
| 93017 | <1% | 365 | $16K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,055 | $15K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 69 | $15K |
| J2704 | Injection, propofol, 10 mg | <1% | 4,485 | $15K |
| 82550 | <1% | 3,358 | $14K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 721 | $14K |
| 84439 | <1% | 1,739 | $14K | |
| 81025 | <1% | 4,050 | $14K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 2,497 | $13K |
| 82728 | <1% | 1,468 | $13K | |
| 73590 | <1% | 878 | $12K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 587 | $12K |
| 77065 | Tomosynthesis, mammo | <1% | 111 | $12K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 574 | $11K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,778 | $11K |
| 80076 | <1% | 2,799 | $11K | |
| 81003 | <1% | 7,961 | $11K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,223 | $11K |
| 71101 | <1% | 568 | $11K | |
| 0760 | <1% | 2,102 | $11K | |
| 82962 | <1% | 4,992 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,091 | $11K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 97 | $10K |
| Z9725 | <1% | 239 | $10K | |
| 82043 | <1% | 1,732 | $10K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 62 | $10K |
| 82570 | <1% | 1,921 | $10K | |
| 86901 | <1% | 4,744 | $10K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 136 | $10K |
| 85380 | <1% | 3,081 | $10K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,220 | $10K |
| 0270 | <1% | 53,950 | $9K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,588 | $9K |
| 86900 | <1% | 4,743 | $9K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 304 | $9K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,404 | $9K |
| 82746 | <1% | 665 | $8K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,804 | $8K |
| 87081 | <1% | 2,229 | $8K | |
| 86803 | <1% | 522 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,003 | $8K |
| 73080 | <1% | 474 | $8K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,093 | $7K |
| 94760 | <1% | 1,849 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,667 | $7K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,367 | $7K |
| 86850 | <1% | 3,193 | $7K | |
| 84100 | <1% | 2,432 | $7K | |
| 72141 | <1% | 54 | $6K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 883 | $6K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 111 | $6K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 715 | $6K |
| 87070 | <1% | 1,142 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,042 | $5K |
| 85652 | <1% | 2,737 | $5K | |
| 84153 | <1% | 311 | $5K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,241 | $5K |
| 74022 | <1% | 248 | $5K | |
| 85007 | <1% | 2,966 | $5K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,277 | $5K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,113 | $5K |
| 97161 | <1% | 769 | $5K | |
| 83550 | <1% | 720 | $4K | |
| 88304 | <1% | 701 | $4K | |
| 86141 | <1% | 659 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,293 | $4K |
| 77049 | <1% | 12 | $4K | |
| 82378 | <1% | 228 | $4K | |
| 87205 | <1% | 1,514 | $4K | |
| 83540 | <1% | 740 | $4K | |
| 82140 | <1% | 427 | $4K | |
| 76870 | <1% | 128 | $3K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 575 | $3K |
| 86140 | <1% | 868 | $3K | |
| 93880 | <1% | 26 | $3K | |
| 71020 | <1% | 206 | $3K | |
| 72070 | <1% | 173 | $3K | |
| 83615 | <1% | 638 | $3K | |
| G0202 | Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | <1% | 41 | $3K |
| 73140 | <1% | 325 | $3K | |
| 0637 | <1% | 4,311 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 589 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 606 | $3K |
| 82553 | <1% | 407 | $3K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 390 | $3K |
| 73090 | <1% | 227 | $3K | |
| 74178 | <1% | 12 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,630 | $3K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 62 | $3K |
| 87147 | <1% | 840 | $3K | |
| 12001 | <1% | 140 | $2K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 1,198 | $2K |
| 93975 | <1% | 13 | $2K | |
| 97597 | <1% | 76 | $2K | |
| 97113 | <1% | 72 | $2K | |
| 80074 | <1% | 57 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,291 | $2K |
| 82607 | <1% | 936 | $2K | |
| 88307 | <1% | 44 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 153 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 523 | $2K |
| 0258 | <1% | 3,504 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 91 | $2K |
| 71010 | <1% | 178 | $2K | |
| 83874 | <1% | 220 | $2K | |
| 70491 | <1% | 13 | $2K | |
| 82010 | <1% | 273 | $1K | |
| 97166 | <1% | 27 | $1K | |
| 0272 | <1% | 3,528 | $1K | |
| V2632 | Posterior chamber intraocular lens | <1% | 12 | $1K |
| C1729 | Catheter, drainage | <1% | 127 | $1K |
| 87430 | <1% | 405 | $1K | |
| 99070 | <1% | 754 | $1K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 446 | $1K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 15,048 | $1K |
| 0710 | <1% | 2,429 | $1K | |
| 70360 | <1% | 84 | $985.42 | |
| 0761 | <1% | 875 | $980.77 | |
| 96523 | <1% | 150 | $971.28 | |
| 72170 | <1% | 77 | $948.52 | |
| 84550 | <1% | 272 | $940.08 | |
| A9270 | Non-covered item or service | <1% | 4,600 | $924.89 |
| 72131 | <1% | 13 | $908.34 | |
| 96402 | <1% | 105 | $878.08 | |
| 84479 | <1% | 214 | $831.96 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 89 | $807.62 |
| 99152 | <1% | 96 | $750.15 | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 24 | $741.45 |
| 86300 | <1% | 82 | $723.12 | |
| 86923 | <1% | 36 | $713.15 | |
| 0360 | <1% | 1,020 | $686.58 | |
| 96411 | <1% | 21 | $682.15 | |
| 87340 | <1% | 85 | $673.83 | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 134 | $630.53 |
| 73552 | <1% | 51 | $624.14 | |
| 82274 | <1% | 40 | $585.71 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 245 | $574.30 |
| 87807 | <1% | 205 | $558.38 | |
| 76882 | <1% | 46 | $550.41 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 255 | $542.67 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 150 | $537.06 |
| 92610 | <1% | 18 | $522.40 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 251 | $512.73 |
| 86308 | <1% | 154 | $498.47 | |
| 10060 | <1% | 41 | $472.64 | |
| 0636 | <1% | 610 | $378.43 | |
| 84156 | <1% | 116 | $371.78 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 179 | $366.07 |
| 85046 | <1% | 86 | $360.09 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 89 | $350.54 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 323 | $349.34 |
| 86780 | <1% | 28 | $332.02 | |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 18 | $318.23 |
| 73060 | <1% | 13 | $318.08 | |
| 99156 | <1% | 125 | $299.37 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 526 | $275.81 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 31 | $254.84 |
| 72072 | <1% | 12 | $245.15 | |
| 12011 | <1% | 13 | $201.60 | |
| 85384 | <1% | 30 | $201.09 | |
| 29125 | <1% | 65 | $194.17 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 35 | $193.96 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,256 | $187.83 |
| 74000 | <1% | 16 | $177.43 | |
| 84436 | <1% | 42 | $177.30 | |
| 82330 | <1% | 26 | $168.56 | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 13 | $162.53 |
| 82803 | <1% | 25 | $160.41 | |
| C9399 | Unclassified drugs or biologicals | <1% | 12 | $146.67 |
| 88342 | <1% | 13 | $135.56 | |
| 84132 | <1% | 153 | $131.84 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 74 | $123.60 |
| 87075 | <1% | 20 | $115.97 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 31 | $115.64 |
| 73120 | <1% | 12 | $114.97 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 60 | $110.09 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 32 | $95.68 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 163 | $90.81 |
| 0324 | <1% | 357 | $77.58 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 35 | $70.54 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 29 | $62.44 |
| 85018 | <1% | 121 | $50.74 | |
| 85014 | <1% | 123 | $49.48 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 25 | $41.25 |
| 82150 | <1% | 12 | $41.22 | |
| 0370 | <1% | 208 | $40.93 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 34 | $36.33 |
| 88311 | <1% | 12 | $27.26 | |
| 36591 | <1% | 752 | $26.26 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 700 | $24.79 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 15 | $24.54 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 76 | $23.04 |
| 82077 | <1% | 53 | $20.82 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 572 | $19.55 |
| 94664 | <1% | 28 | $16.91 | |
| 84295 | <1% | 56 | $14.78 | |
| 82947 | <1% | 41 | $14.46 | |
| 85049 | <1% | 13 | $12.06 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 21 | $11.42 |
| 82435 | <1% | 25 | $3.67 | |
| 0305 | 0% | 571 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 34 | $0.00 |
| 0306 | 0% | 711 | $0.00 | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | 0% | 18 | $0.00 |
| 0949 | 0% | 114 | $0.00 | |
| 0401 | 0% | 24 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 15 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| 0307 | 0% | 116 | $0.00 | |
| 0301 | 0% | 1,855 | $0.00 | |
| 0335 | 0% | 76 | $0.00 | |
| 0922 | 0% | 34 | $0.00 | |
| 0610 | 0% | 20 | $0.00 | |
| 0420 | 0% | 193 | $0.00 | |
| 0372 | 0% | 30 | $0.00 | |
| 0310 | 0% | 70 | $0.00 | |
| 0331 | 0% | 22 | $0.00 | |
| 80050 | General health panel | 0% | 29 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 13 | $0.00 |
| 0352 | 0% | 171 | $0.00 | |
| 0351 | 0% | 118 | $0.00 | |
| 0300 | 0% | 1,277 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 305 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 263 | $0.00 |
| 0750 | 0% | 54 | $0.00 | |
| 0320 | 0% | 279 | $0.00 | |
| 0302 | 0% | 22 | $0.00 | |
| 0402 | 0% | 242 | $0.00 | |
| 0403 | 0% | 22 | $0.00 | |
| 0361 | 0% | 25 | $0.00 | |
| 0260 | 0% | 119 | $0.00 | |
| 0278 | 0% | 38 | $0.00 | |
| 0921 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY ENROLLMENTS)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.